Wide Ranks

KRON

Kronos Bio, Inc.

0.9601

Top Statistics
Market Cap 57 M Forward PE -0.6957 Revenue Growth 44.20 %
Current Ratio 8.48 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.6180 Enterprise / Revenue -6.92 Price To Sales Trailing12 Months 6.89
Profitability
Profit Margins 0.00 % Operating Margins -649.00 %
Balance Sheet
Total Cash 136 M Total Cash Per Share 2.27 Total Debt 27 M
Total Debt To Equity 22.03 Current Ratio 8.48 Book Value Per Share 2.70
All Measures
Short Ratio 881.00 % Message Board Id finmb_559411734 Shares Short Prior Month 714171
Return On Equity -0.6300 City San Mateo Uuid 6f8f728e-bb6c-3b57-873b-3a705e9ece7a
Previous Close 0.8650 First Trade Date Epoch Utc 1 B Book Value 2.70
Beta 1.86 Total Debt 27 M Volume 1 M
Price To Book 0.3557 Fifty Two Week Low 0.6900 Total Cash Per Share 2.27
Total Revenue 8 M Shares Short Previous Month Date 1 B Target Median Price 1.62
Audit Risk 7 Max Age 86400 Recommendation Mean 2.67
Sand P52 Week Change 0.3133 Operating Margins -649.00 % Target Mean Price 1.62
Net Income To Common -102851000 Short Percent Of Float 0.0115 Implied Shares Outstanding 60 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 462320
Average Volume10days 462320 Total Cash 136 M Next Fiscal Year End 1 B
Revenue Per Share 0.1430 Held Percent Insiders 0.2690 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 0.8650 Target Low Price 1.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.9375 Open 0.9300 Free Cashflow -43455876
State CA Dividend Yield 0.00 % Return On Assets -0.2828
Time Zone Short Name EST Board Risk 6 Trailing Eps -1.43
Day Low 0.9200 Address1 1300 South El Camino Real Shares Outstanding 60 M
Compensation Risk 8 Price Hint 4 Target High Price 2.25
Website https://www.kronosbio.com 52 Week Change -0.1933 Average Volume 134237
Forward Eps -1.38 Recommendation Key hold Compensation As Of Epoch Date 1 B
Quick Ratio 821.20 % Is_sp_500 False Regular Market Day High 0.9899
Profit Margins 0.00 % Debt To Equity 22.03 Fifty Two Week High 1.60
Day High 0.9899 Shares Short 527682 Regular Market Open 0.9300
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue -6.92
Revenue Growth 44.20 % Shares Percent Shares Out 0.0088 Operating Cashflow -87839000
Currency USD Time Zone Full Name America/New_York Market Cap 57 M
Is_nasdaq_100 False Zip 94402 Quote Type EQUITY
Industry Biotechnology Long Name Kronos Bio, Inc. Overall Risk 7
Regular Market Day Low 0.9200 Held Percent Institutions 0.3267 Current Price 0.9601
Address2 Suite 400 Enterprise To Ebitda 0.6180 Financial Currency USD
Current Ratio 8.48 Gross Margins 100.00 % Industry Disp Biotechnology
Number Of Analyst Opinions 2 Country United States Float Shares 42 M
Two Hundred Day Average 1.05 Governance Epoch Date 1 B Enterprise Value -58203288
Price To Sales Trailing12 Months 6.89 Forward PE -0.6957 Regular Market Volume 1 M
Ebitda -94241000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States.

Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.

The company was incorporated in 2017 and is headquartered in San Mateo, California.